Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete, page-71

Below is just my rough interpretation & rough rounded $$ figures. Any comments welcome.

I guess they have some serious R&D $$ to sprinkle some more of that 'pixie dust' you mention bigwilllly.

Approx A$55 Mil anywhere in the world pixie dust + 43.5% rebate on local pixie dust spend. The A$55 Mil has to be sprinkled by June 2025 so approx. 1 year to do the business.

They have 'pulled' an A$11Mil loan at 15% interest against the A$11 Mil rebate already - early March 2024

Interesting that there is a 50% rule - see below - i.e overseas findings cannot be more than 50% of the R&D spend. If this is the case then RCE need to spend approx. A$55 Mil in Australia before June 2025 to be able to claim the full A$55 Mil refund - i.e. A$110 Mil total spend with 50% i.e. A$55 Mil being spend overseas.

A$10Mil from this CR

Seems like a LOT will have to happen in the next year AND to get the full overseas spend of A$55 Mil they need to spend A$55 Mil - 43.5% rebate I assume ? ... so approx. A$31 Mil actual RCE $$ to be spent locally.

They had A$8.5Mil in cash at the end of last quarter SO there has to be another CR coming to get the extra approx. A$12 Mil required to be spent to be able to claim the full overseas R&D findings $$$

Hopefully that CR will be early 2025 AFTER so decent results from the upcoming future trials & an increase in SP so as not to be so dilutive.

RCE really need to get some decisive, unambiguous runs on the board to get the SP up ASAP.




https://www.bulletpoint.com.au/rd-tax-incentive-overseas-finding/